Watson's Generic Lovenox Launches At Risk; Will Sanofi's Authorized Generic Follow? An appeals court lifted a preliminary injunction that blocked Amphastar and U.S. marketing partner Watson from selling their generic version of Sanofi's blood thinner. Watson is to launch immediately in the U.S.
LEO Plays Up Rapid Action Of Picato For Actinic Keratosis Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.
HHS Proposed Drug Coverage Standard For State Exchange Plans Is Well Below Currently Available Coverage - Avalere Study Study finds that HHS' proposed minimum standard of one drug per class on plan formularies could result in drug coverage that is significantly more limited than what is currently offered in the individual and small group market.
Ariad: Worth Watching As Its Pipeline Matures On the verge of getting its first chance at being a commercialization company, Ariad has lofty plans to become a global leader in oncology.
Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012 With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.
Amgen Gobbles Up Micromet In $1.16 Billion BiTE With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
Celgene Bolsters Pipeline With Avila Acquisition Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila's lead compound as well as other compounds to emerge from its technology platform.
"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here